TCR Mimics
Keyway™ TCRm discovery for next-gen immunotherapies
Target the undruggable and discover TCRms that open a wide range of intracellular opportunities
Unlike traditional antibodies that are limited to targeting extracellular antigens, TCRm antibodies mimic the function of T-cell receptors by targeting fragments of intracellular antigens presented on cell surface MHC molecules (pMHC complexes). TCRms can be incorporated into CD3 based cell engagers to drive potent killing of tumors or virally infected cells.
Highly-specific human TCRm discovery
Optimized CD3 binders
Multispecific engineering
Functional validation
Create engineered antibodies that mimic natural T-cell receptors (TCRs) with our end-to-end Keyway™ TCRm antibody discovery service. Keyway technology accelerates the development of highly targeted, immune cell engagers, providing your project with a robust, scalable solution for advancing innovative treatments.
Revolutionizing TCRm discovery with precision, safety, and efficacy
Leverage proprietary technologies
The Keyway TCRm Discovery Platform combines Alloy’s in vivo, in vitro, and in silico capabilities to identify and optimize antibodies binding to specific pMHC complexes. It includes pMHC display libraries for testing specificity and minimizing off-target effects in therapeutic TCRm discovery.
Optimized for clinical efficacy
Our services incorporate proprietary protocols and workflows to consistently deliver TCRm leads that are optimized for the clinic across several key areas including safety, specificity, stability, efficacy, and manufacturing.
Pioneered by leading TCRm experts
Keyway is led by pioneering researchers in the TCR field who advanced the first TCRm into clinical trials for hematological cancers.
The Keyway TCRm end-to-end solution
Our Keyway™ TCRm platform builds on Alloy’s world-class in vivo discovery platforms to create peptide-MHC (pMHC) targeted antibodies with unmatched specificity and affinity.
Lead Discovery
Generate best-in-class fully human antibodies against peptide-MHC targets
Our Keyway TCRm platform builds on Alloy’s world-class in vivo discovery platforms to create peptide-MHC (pMHC) targeted antibodies with unmatched specificity and affinity.
Peptide MHC production
Each project starts with the production and QC of high-quality pMHC complexes, utilizing proprietary protocols to produce consistent antigens optimized for immunization and screening.
Discovery
Discovery campaigns are performed with Alloy’s suite of transgenic mice combined with our advanced workflows including single B-cell sorting or yeast immune libraries, deep sequencing, and in silico clone selection to find the optimal hits.
Characterization
All antibodies are characterized for affinity, specificity, cell binding, and developability, ensuring that your therapeutic leads meet the highest quality standards.
Specificity
Rigorous specificity screening with X-scan to develop safe and efficacious drugs
Rigorous specificity screening is incorporated throughout the discovery workflow to ensure your TCRm therapeutics specifically target your pMHC of interest without hitting off-target peptide antigens.
Our proprietary X-Scan platform determines the precise peptide binding motif of your lead TCRm candidates and tests for off-target binding across the entire human proteome to eliminate polyreactivity and deliver drug candidates optimized for safety and efficacy.
Optimized for the Clinic
Engineering and functional testing for the best outcome
Keyway offers TCRm engineering into your preferred output and leverages our translational medicine capabilities for in vivo and in vitro functional testing
Bispecific cell engagers
Multiple proprietary T-cell engagers (including CD3 and CD28) and high-throughput bispecific generation and screening.
CAR-T engineering
mRNA-and lentiviral-based vector system producing CAR-Ts and characterization.
Functional testing
Translational medicine gives early insights into the functional activity of candidates generated from Keyway TCR discovery projects.
Start your TCRm campaign
We’ll work together to find you the best therapeutic TCRm to achieve your cancer immunotherapy pipeline goals.
